Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction of complementary immunogenic necroptosis and apoptosis cell death pathways inhibits cancer metastasis and relapse.
Egbulefu C, Black K, Su X, Karmakar P, Habimana-Griffin L, Sudlow G, Prior J, Chukwu E, Zheleznyak A, Xu B, Xu Y, Esser A, Mixdorf M, Moss E, Manion B, Reed N, Gubin M, Lin CY, Schreiber R, Weilbaecher K, Achilefu S. Egbulefu C, et al. Among authors: zheleznyak a. Res Sq [Preprint]. 2024 Mar 12:rs.3.rs-3992212. doi: 10.21203/rs.3.rs-3992212/v1. Res Sq. 2024. PMID: 38558990 Free PMC article. Preprint.
Development of New CD38 Targeted Peptides for Cancer Imaging.
Zheleznyak A, Tang R, Duncan K, Manion B, Liang K, Xu B, Vanover A, Ghai A, Prior J, Lees S, Achilefu S, Kelly K, Shokeen M. Zheleznyak A, et al. Mol Imaging Biol. 2024 Mar 13. doi: 10.1007/s11307-024-01901-5. Online ahead of print. Mol Imaging Biol. 2024. PMID: 38480650
p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy.
Faget DV, Luo X, Inkman MJ, Ren Q, Su X, Ding K, Waters MR, Raut GK, Pandey G, Dodhiawala PB, Ramalho-Oliveira R, Ye J, Cole T, Murali B, Zheleznyak A, Shokeen M, Weiss KR, Monahan JB, DeSelm CJ, Lee AV, Oesterreich S, Weilbaecher KN, Zhang J, DeNardo DG, Stewart SA. Faget DV, et al. Among authors: zheleznyak a. Cancer Discov. 2023 Jun 2;13(6):1454-1477. doi: 10.1158/2159-8290.CD-22-0907. Cancer Discov. 2023. PMID: 36883955 Free PMC article.
Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
Ghai A, Zheleznyak A, Mixdorf M, O'Neal J, Ritchey J, Rettig M, DiPersio J, Shokeen M, Achilefu S. Ghai A, et al. Among authors: zheleznyak a. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1302-1311. doi: 10.1007/s00259-020-05097-y. Epub 2020 Nov 11. Eur J Nucl Med Mol Imaging. 2021. PMID: 33179150 Free PMC article.
Nanotherapeutics for multiple myeloma.
Zheleznyak A, Shokeen M, Achilefu S. Zheleznyak A, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Nov;10(6):e1526. doi: 10.1002/wnan.1526. Epub 2018 Apr 26. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018. PMID: 29701006 Free PMC article. Review.
Deficiency of the adaptor protein SLy1 results in a natural killer cell ribosomopathy affecting tumor clearance.
Arefanian S, Schäll D, Chang S, Ghasemi R, Higashikubo R, Zheleznyak A, Guo Y, Yu J, Asgharian H, Li W, Gelman AE, Kreisel D, French AR, Zaher H, Plougastel-Douglas B, Maggi L, Yokoyama W, Beer-Hammer S, Krupnick AS. Arefanian S, et al. Among authors: zheleznyak a. Oncoimmunology. 2016 Sep 27;5(12):e1238543. doi: 10.1080/2162402X.2016.1238543. eCollection 2016. Oncoimmunology. 2016. PMID: 28123874 Free PMC article.
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.
Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno BM, Higashikubo R, Gelman AE, Kreisel D, Fremont DH, Krupnick AS. Ghasemi R, et al. Among authors: zheleznyak a. Nat Commun. 2016 Sep 21;7:12878. doi: 10.1038/ncomms12878. Nat Commun. 2016. PMID: 27650575 Free PMC article.
36 results